February 19, 2026
A Texas federal judge has upheld a jury's finding that genetic testing company Natera Inc. committed literal infringement of a patent held by Ravgen Inc., but said Ravgen's expert testimony wasn't enough to support the jury's finding of infringement under the doctrine of equivalents.
January 16, 2024
A Texas federal jury found Tuesday afternoon that genetic testing company Natera infringed a patent from rival Ravgen, awarding the Maryland-based biotech firm $57 million in damages, according to both parties.
January 11, 2024
A Texas federal judge has denied a bid from genetic testing business Natera Inc. for a win on its argument that it did not infringe claims in a patent owned by a small biotech business, saying Natera had a flawed argument on elements of those claims.
December 11, 2023
A small biotech business plans to use the web of settlement agreements it has landed since netting a blockbuster jury verdict last year to ask jurors to award it $410 million early next year, though the bid is opening the company up to arguments that nobody wanted to buy its patents before getting dragged into court.
February 16, 2023
A Texas federal judge has rebuffed a bid by biotechnology company Ravgen to transfer its genetic testing patent suit against a rival back to U.S. District Judge Alan Albright's courtroom after Ravgen, the patent owner, scored a nine-figure judgment there, citing concerns about "potential mischief" behind the requested venue change.